Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Readi-Cat2

×

Overview

What is Readi-Cat2?

READI-CAT 2

Inactive Ingredients

BANANA SMOOTHIE READI-CAT 2

Inactive Ingredients

CREAMY VANILLA SMOOTHIE READI-CAT 2

Inactive Ingredients

BERRY SMOOTHIE READI-CAT 2

Inactive Ingredients

MOCHACCINO SMOOTHIE READI-CAT 2

Inactive Ingredients



What does Readi-Cat2 look like?



What are the available doses of Readi-Cat2?

Sorry No records found.

What should I talk to my health care provider before I take Readi-Cat2?

Sorry No records found

How should I use Readi-Cat2?

For use in Computed Tomography to opacify the GI tract.

The volume and concentration of the CT barium sulfate suspension to be administered will depend on the degree and extent of contrast required in the area(s) under examination and on the equipment and technique employed.

Suggested 30 Minute Barium Administration Protocol for Abdomen Studies:

Suggested 90 Minute Barium Administration Protocol for Abdomen/Pelvis Studies:


What interacts with Readi-Cat2?

This product should not be used in patients with known or suspected gastric or intestinal perforation, or hypersensitivity to barium sulfate or any component of this barium sulfate formulation.



What are the warnings of Readi-Cat2?

Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.


What are the precautions of Readi-Cat2?

General

Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease. Ingestion of barium is not recommended in patients with a history of food aspiration. If barium studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. If barium is aspirated into the larynx, further administration should be immediately discontinued. After any barium study of the GI tract, it is important to rehydrate the patient as quickly as possible to prevent impaction of the barium. To prevent barium impaction in the colon, the use of mild laxatives such as milk of magnesia or lactulose following completion of the examination may also be required. These mild laxatives are recommended on a routine basis and in patients with a history of constipation unless clinically contraindicated.

Information for Patients

  • if they are pregnant.
  • if they are allergic to any foods or medication, or if they have had any prior reactions to barium sulfate products or other x-ray contrast agents.
  • if they are currently taking any medications, have any serious medical condition for which they are being treated or followed, or had any recent surgery.
  • seek immediate medical attention if they experience an allergic reaction after using this product.


Before using this product patients should be instructed to tell the physician ordering the procedure and the imaging technologist:

Drug Interactions

The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.

Usage in Pregnancy

Radiation is known to cause harm to the unborn fetus exposed . Therefore, radiographic procedures should only be used when, in the judgement of the physician, its use is deemed essential to the welfare of the pregnant patient.

Nursing Mothers

Barium sulfate products may be used during lactation.


What are the side effects of Readi-Cat2?

Sorry No records found


What should I look out for while using Readi-Cat2?

This product should not be used in patients with known or suspected gastric or intestinal perforation, or hypersensitivity to barium sulfate or any component of this barium sulfate formulation.

Due to the increased likelihood of allergic reactions in atopic patients, it is important that a complete history of known and suspected allergies as well as allergiclike symptoms, e.g., rhinitis, bronchial asthma, eczema and urticaria, must be obtained prior to any medical procedure utilizing these products. A mild allergic reaction would most likely include generalized pruritus, erythema or urticaria (approximately 1 in 250,000). Such reactions will generally respond to an antihistamine such as 50 mg of diphenhydramine or its equivalent. In the rarer, more serious reactions (approximately 1 in 1,000,000) laryngeal edema, bronchospasm or hypotension could develop. Severe reactions which may require emergency measures are often characterized by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea, agitation, confusion and cyanosis, progressing to unconsciousness. Treatment should be initiated immediately with 0.3 to 0.5 cc of 1:1000 epinephrine subcutaneously. If bronchospasm predominates, 0.25 to 0.50 grams of intravenous aminophylline should be given slowly. Appropriate vasopressors might be required. Adrenocorticosteroids, even if given intravenously, exert no significant effect on the acute allergic reactions for a few hours. The administration of these agents should not be regarded as emergency measures for the treatment of allergic reactions.

Apprehensive patients may develop weakness, pallor, tinnitus, diaphoresis and bradycardia following the administration of any diagnostic agent. Such reactions are usually non-allergic in nature and are best treated by having the patient lie flat for an additional 10 to 30 minutes under observation.


What might happen if I take too much Readi-Cat2?

On rare occasions following repeated administration, severe stomach cramps, nausea, vomiting, diarrhea or constipation may occur. These indicated responses can be present in both fluoroscopic and CT procedures. These are transitory in nature and are not considered serious. Symptoms may be treated according to currently accepted standards of medical care.


How should I store and handle Readi-Cat2?

Store at 20°C to 25°C (68°F to 77°F) [See USP controlled room temperature]. Protect from moisture.READI-CAT 2BANANA SMOOTHIE READI-CAT 2CREAMY VANILLA SMOOTHIE READI-CAT 2BERRY SMOOTHIE READI-CAT 2MOCHACCINO SMOOTHIE READI-CAT 2SHAKE WELL PRIOR TO USEManufactured by E-Z-EM Canada Inc. for E-Z-EM, Inc., a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel. 1-516-333-8230 1-800 544-4624rev. 11/13 TX1665-1READI-CAT 2BANANA SMOOTHIE READI-CAT 2CREAMY VANILLA SMOOTHIE READI-CAT 2BERRY SMOOTHIE READI-CAT 2MOCHACCINO SMOOTHIE READI-CAT 2SHAKE WELL PRIOR TO USEManufactured by E-Z-EM Canada Inc. for E-Z-EM, Inc., a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel. 1-516-333-8230 1-800 544-4624rev. 11/13 TX1665-1READI-CAT 2BANANA SMOOTHIE READI-CAT 2CREAMY VANILLA SMOOTHIE READI-CAT 2BERRY SMOOTHIE READI-CAT 2MOCHACCINO SMOOTHIE READI-CAT 2SHAKE WELL PRIOR TO USEManufactured by E-Z-EM Canada Inc. for E-Z-EM, Inc., a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel. 1-516-333-8230 1-800 544-4624rev. 11/13 TX1665-1READI-CAT 2BANANA SMOOTHIE READI-CAT 2CREAMY VANILLA SMOOTHIE READI-CAT 2BERRY SMOOTHIE READI-CAT 2MOCHACCINO SMOOTHIE READI-CAT 2SHAKE WELL PRIOR TO USEManufactured by E-Z-EM Canada Inc. for E-Z-EM, Inc., a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel. 1-516-333-8230 1-800 544-4624rev. 11/13 TX1665-1READI-CAT 2BANANA SMOOTHIE READI-CAT 2CREAMY VANILLA SMOOTHIE READI-CAT 2BERRY SMOOTHIE READI-CAT 2MOCHACCINO SMOOTHIE READI-CAT 2SHAKE WELL PRIOR TO USEManufactured by E-Z-EM Canada Inc. for E-Z-EM, Inc., a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel. 1-516-333-8230 1-800 544-4624rev. 11/13 TX1665-1READI-CAT 2BANANA SMOOTHIE READI-CAT 2CREAMY VANILLA SMOOTHIE READI-CAT 2BERRY SMOOTHIE READI-CAT 2MOCHACCINO SMOOTHIE READI-CAT 2SHAKE WELL PRIOR TO USEManufactured by E-Z-EM Canada Inc. for E-Z-EM, Inc., a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel. 1-516-333-8230 1-800 544-4624rev. 11/13 TX1665-1READI-CAT 2BANANA SMOOTHIE READI-CAT 2CREAMY VANILLA SMOOTHIE READI-CAT 2BERRY SMOOTHIE READI-CAT 2MOCHACCINO SMOOTHIE READI-CAT 2SHAKE WELL PRIOR TO USEManufactured by E-Z-EM Canada Inc. for E-Z-EM, Inc., a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel. 1-516-333-8230 1-800 544-4624rev. 11/13 TX1665-1READI-CAT 2BANANA SMOOTHIE READI-CAT 2CREAMY VANILLA SMOOTHIE READI-CAT 2BERRY SMOOTHIE READI-CAT 2MOCHACCINO SMOOTHIE READI-CAT 2SHAKE WELL PRIOR TO USEManufactured by E-Z-EM Canada Inc. for E-Z-EM, Inc., a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel. 1-516-333-8230 1-800 544-4624rev. 11/13 TX1665-1


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Barium sulfate, due to its high molecular density is opaque to x-rays and, therefore, acts as a positive contrast agent for radiographic studies. Barium sulfate is biologically inert and, therefore, is not absorbed or metabolized by the body, and is eliminated from the GI tract unchanged.

Non-Clinical Toxicology
This product should not be used in patients with known or suspected gastric or intestinal perforation, or hypersensitivity to barium sulfate or any component of this barium sulfate formulation.

Due to the increased likelihood of allergic reactions in atopic patients, it is important that a complete history of known and suspected allergies as well as allergiclike symptoms, e.g., rhinitis, bronchial asthma, eczema and urticaria, must be obtained prior to any medical procedure utilizing these products. A mild allergic reaction would most likely include generalized pruritus, erythema or urticaria (approximately 1 in 250,000). Such reactions will generally respond to an antihistamine such as 50 mg of diphenhydramine or its equivalent. In the rarer, more serious reactions (approximately 1 in 1,000,000) laryngeal edema, bronchospasm or hypotension could develop. Severe reactions which may require emergency measures are often characterized by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea, agitation, confusion and cyanosis, progressing to unconsciousness. Treatment should be initiated immediately with 0.3 to 0.5 cc of 1:1000 epinephrine subcutaneously. If bronchospasm predominates, 0.25 to 0.50 grams of intravenous aminophylline should be given slowly. Appropriate vasopressors might be required. Adrenocorticosteroids, even if given intravenously, exert no significant effect on the acute allergic reactions for a few hours. The administration of these agents should not be regarded as emergency measures for the treatment of allergic reactions.

Apprehensive patients may develop weakness, pallor, tinnitus, diaphoresis and bradycardia following the administration of any diagnostic agent. Such reactions are usually non-allergic in nature and are best treated by having the patient lie flat for an additional 10 to 30 minutes under observation.

The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.

Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease. Ingestion of barium is not recommended in patients with a history of food aspiration. If barium studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. If barium is aspirated into the larynx, further administration should be immediately discontinued. After any barium study of the GI tract, it is important to rehydrate the patient as quickly as possible to prevent impaction of the barium. To prevent barium impaction in the colon, the use of mild laxatives such as milk of magnesia or lactulose following completion of the examination may also be required. These mild laxatives are recommended on a routine basis and in patients with a history of constipation unless clinically contraindicated.

Adverse reactions, such as nausea, vomiting, diarrhea and abdominal cramping, accompanying the use of barium sulfate formulations are infrequent and usually mild. Severe reactions (approximately 1 in 1,000,000) and fatalities (approximately 1 in 10,000,000) have occurred. Procedural complications are rare, but may include aspiration pneumonitis, barium impaction, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities. EKG changes have been reported following or during barium enema procedures. It is of the utmost importance to be completely prepared to treat any such occurrence.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).